Till sidinnehåll
Inloggad som:

Magnetismm-5

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

Magnetismm-5
En fas 3-studie av elranatamab (PF-06863135) som monoterapi och elranatamab + daratumumab jämfört med daratumumab + pomalidomid + dexametason hos deltagare med recidiverande/refraktärt multipelt myelom
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
PLACEHOLDER
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
Mer information om studien för vårdgivare
 Participants age ≥18 years (or the minimum country-specific age of consent if >18).  Prior diagnosis of multiple myeloma (MM) as defined according to IMWG criteria. See link for more info
 Smoldering MM.  Plasma cell leukemia.  Amyloidosis, Waldenström’s macroglobulinemia, or polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) Syndrome.
Behandling
Fas 3
Kurativ
Ej tillämpbar
Företag
Studien ändrades senast: (2025-09-30)
Tillbaka till listan